Holen Sie sich die Stockscreener-App
21.61
3.83%
-0.86
Handel nachbörslich:
21.80
0.19
+0.88%
Schlusskurs vom Vortag:
$22.47
Offen:
$22.46
24-Stunden-Volumen:
1.24M
Relative Volume:
0.90
Marktkapitalisierung:
$3.66B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
120.06
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
-7.89%
1M Leistung:
-18.73%
6M Leistung:
-15.09%
1J Leistung:
+13.14%
1-Tages-Spanne:
$21.51
$22.58
1-Wochen-Bereich:
$21.51
$24.04
52-Wochen-Spanne:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
21.61 | 3.80B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - Barchart.com
Glioblastoma Pipeline 2025: Therapies Under Investigation, - openPR.com
Understanding Momentum Shifts in (ACAD) - Stock Traders Daily
ACADIA’s ACP-211 Trial Targets Difficult-to-Treat Depression: What Investors Should Watch - TipRanks
Candriam S.C.A. Buys New Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Insider Selling: ACADIA Pharmaceuticals (NASDAQ:ACAD) EVP Sells 6,950 Shares of Stock - MarketBeat
ACADIA Pharmaceuticals Inc. (ACAD): Investor Outlook Reveals 34% Upside Potential Amid Robust CNS Pipeline - DirectorsTalk Interviews
ACADIA Pharmaceuticals: Biotech Optimism Meets Volatile Reality After A Sharp Pullback - AD HOC NEWS
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Shares Lagging The Market But So Is The Business - 富途牛牛
ACAD: Oppenheimer Raises Price Target to $23, Maintains Rating | - GuruFocus
Oppenheimer Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Acadia Pharmaceuticals stock price target raised to $23 from $21 at Oppenheimer - Investing.com Canada
Aug EndMonth: How do insiders feel about ACADIA Pharmaceuticals IncEarnings Risk Report & Capital Protection Trading Alerts - baoquankhu1.vn
ACADIA Pharmaceuticals (ACAD) Is Down 5.5% After EMA Trend Vote Goes Against Daybue In Europe - Sahm
Analysts Are Neutral on Top Healthcare Stocks: Replimune Group (REPL), ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
European regulators unlikely to recommend approval of Daybue - Rett Syndrome News
Analysts Are Bullish on Top Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Acadia Pharmaceuticals Shares Drop After Phase 3 PWS Trial Misses Primary Goal - MSN
A Glimpse Into The Expert Outlook On ACADIA Pharmaceuticals Through 11 Analysts - Benzinga
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Cuts Target Price to $31 - 富途牛牛
EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug - Benzinga
ACAD Maintains Outperform Rating Despite Lowered Price Target | - GuruFocus
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
Acadia Pharmaceuticals stock price target lowered to $31 at RBC Capital - Investing.com Canada
EU Not The Land Of Plenty For Acadia After Rett Therapy Snub - Citeline News & Insights
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView
ACADIA Pharmaceuticals (ACAD) Analyst Rating Reaffirmed by Citiz - GuruFocus
Citizens Jmp Reiterates Market Outperform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
ACAD: HC Wainwright & Co. Reiterates Buy Rating with $37 Target - GuruFocus
Acadia Pharmaceuticals stock faces EMA hurdle for Rett syndrome drug By Investing.com - Investing.com Canada
Acadia Pharmaceuticals stock faces setback as CHMP signals negative vote By Investing.com - Investing.com Canada
HC Wainwright Reiterates Buy Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD) - MarketBeat
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU - Eastern Progress
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union - BioSpace
The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval - Yahoo Finance
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Strong One Year Share Price Gain? - Sahm
CHMP signals negative stance on Acadia's Rett syndrome drug ahead of opinion - FirstWord Pharma
Acadia Faces EMA Setback On Rett Drug As Regulatory Test Looms - Yahoo Finance
Is It Too Late To Consider ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Rebound? - Yahoo Finance
Acadia faces setback in EU approval for Rett syndrome treatment By Investing.com - Investing.com India
Neuren Faces EU Setback as EMA Panel Issues Negative Trend Vote on Trofinetide for Rett Syndrome - TipRanks
Acadia Pharmaceuticals Provides Update on Regulatory Submission f - The National Law Review
Acadia Pharma down after negative EU trend vote on neurological disorder drug - TradingView
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug - Investing.com
ACADIA Pharmaceuticals stock falls after negative EU regulatory vote on Rett drug By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals Submits Marketing Authorization Application for Trofinetide to European Medicines Agency - geneonline.com
Why Did ACAD Stock Slump 8% After Hours Today? - Stocktwits
Acadia faces setback in EU approval for Rett syndrome treatment - Investing.com
Acadia Pharmaceuticals (ACAD) Encounters Hurdle in EU Approval f - GuruFocus
Acadia Pharmaceuticals provides update on regulatory submission for trofinetide for the treatment of Rett syndrome in the European Union - marketscreener.com
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):